Trial reportSexually transmitted infections2006
Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.
Trial report in Sexually transmitted infections, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 7 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Antibiotic therapy for pelvic inflammatory disease.The Cochrane database of systematic reviews · 2020Pooled it
- Antibiotic therapy for pelvic inflammatory disease: an abridged version of a Cochrane systematic review and meta-analysis of randomised controlled trials.Sexually transmitted infections · 2019Pooled it
- Antibiotic therapy for pelvic inflammatory disease.The Cochrane database of systematic reviews · 2017Pooled it
- Sexually transmitted diseases treatment guidelines, 2015.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2015Guideline
- Pelvic inflammatory disease.BMJ clinical evidence · 2013Pooled it
- Improving adherence to guidelines for the diagnosis and management of pelvic inflammatory disease: a systematic review.Infectious diseases in obstetrics and gynecology · 2012Pooled it
- Pelvic inflammatory disease.BMJ clinical evidence · 2008Pooled it
- Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013Trial
- Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Article
- Mycoplasma genitalium: An Overlooked Sexually Transmitted Pathogen in Women?Infectious diseases in obstetrics and gynecology · 2016Review
- Gender analysis of moxifloxacin clinical trials.Journal of women's health (2002) · 2014Review
- Controversies in family planning: postabortal pelvic inflammatory disease.Contraception · 2013Review
- Mycoplasma genitalium: should we treat and how?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis multinational, multicentre, prospective, randomised, double blind, parallel group, non-inferiority study compared the efficacy and safety of moxifloxacin monotherapy with ofloxacin plus metronidazole in women with uncomplicated pelvic inflammatory disease.
methodsWomen from hospitals throughout 13 countries received a 14 day course of either oral moxifloxacin, 400 mg once daily (n = 384), or oral ofloxacin, 400 mg twice daily plus oral metronidazole, 500 mg twice daily (n = 365).
resultsOf the 741 patients in the intent to treat (ITT) population, 564 (74.2%) were valid for the per protocol (PP) analyses; 112 (19.9%) of these were included in the microbiologically valid population (MBV). Clinical resolution rates in the PP population at the test of cure visit (TOC, 5-24 days post-therapy, primary efficacy end point) were 90.2% (248/275) for moxifloxacin and 90.7% (262/289) for ofloxacin plus metronidazole (95% CI: -5.7% to 4.0%). At follow up (28-42 days post-therapy), resolution rates in the PP population were 85.8% (236/275) and 87.9% (254/289) for moxifloxacin and comparator, respectively (95% CI: -8.0% to 3.1%). Bacteriological success rates in the MBV population at TOC were 87.5% (49/56) for moxifloxacin and 82.1% (46/56) for comparator (95% CI: -8.3% to 18.8%). Against Chlamydia trachomatis and Neisseria gonorrhoeae, bacteriological success rates with moxifloxacin were 88.5% (23/26) and 100% (13/13) and for comparator 85.7% (18/21) and 81.8% (18/22), respectively. Drug related adverse events occurred less frequently with moxifloxacin (22.5% (85/378)) versus the comparator (30.9% (112/363)) (p = 0.01).
conclusionIn uncomplicated PID, once daily moxifloxacin monotherapy was clinically and bacteriologically as efficacious as twice daily ofloxacin plus metronidazole therapy and was associated with fewer drug related adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.